Watch the On Demand video
Redefining the Treatment of Newly Diagnosed mIDH1 AML patients non-eligible for intensive therapy
Hier nog een stukje subtitel
25.03.2025
Presentations in this webinar
Prof Johan Maertens, MD, PhD
Background of IDH1 mutations in ND-AML
Koen Theunissent, MD, PhD
Molecular testing and treatment outcomes in AML
Stéphane de Botton, MD, PhD
Key data and practical use of ivosidenib in mIDH1 AML
Complete video
Redefining the Treatment of Newly Diagnosed mIDH1 AML patients non-eligible for intensive therapy